Denali Therapeutics Inc DNLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
-
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
-
Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips
-
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
-
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint
Trading Information
- Previous Close Price
- $28.22
- Day Range
- $28.38–28.97
- 52-Week Range
- $14.56–32.13
- Bid/Ask
- $28.62 / $29.10
- Market Cap
- $4.10 Bil
- Volume/Avg
- 360,601 / 962,766
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3,356.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 364
Comparables
Valuation
|
Metric
|
DNLI
|
RCKT
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.95 | 3.88 | 5.21 |
Price/Sales | 3,356.39 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
DNLI
RCKT
EWTX
Financial Strength
|
Metric
|
DNLI
|
RCKT
|
EWTX
|
|---|---|---|---|
Quick Ratio | 12.02 | 7.42 | 29.79 |
Current Ratio | 12.46 | 7.79 | 30.24 |
Interest Coverage | — | −143.43 | — |
Quick Ratio
DNLI
RCKT
EWTX
Profitability
|
Metric
|
DNLI
|
RCKT
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −25.60% | −41.09% | −23.23% |
Return on Equity (Normalized) | −28.09% | −46.72% | −24.43% |
Return on Invested Capital (Normalized) | −30.69% | −47.69% | −29.19% |
Return on Assets
DNLI
RCKT
EWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kxtdgwkdr | Jwgf | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bjvcpsj | Wgtrr | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nlbfrqsyb | Pgwts | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qgdjfdb | Rdvbxc | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Hwmjwgrpz | Trwg | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xqdjsdjp | Sbsn | $29.2 Bil | |||
| Moderna Inc
MRNA
| Xbmrwdmqs | Nqn | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jxgqlvbxw | Pwfn | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jjcdfqv | Nwbwfp | $13.2 Bil | |||
| Incyte Corp
INCY
| Wspjcrqn | Jqmpv | $13.0 Bil |
United States